Edoxaban (Lixiana) is recommended as an option for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation who have one or more risk factors, such as:

  • heart failure, high blood pressure or diabetes
  • had a stroke or transient ischaemic attack before
  • aged 75 years or older.

What does this mean for me?

If you have non valvular atrial fibrillation and your doctor thinks that edoxaban is the right treatment, you should be able to have the treatment on the NHS.

Edoxaban should be available on the NHS within 3 months of the guidance being issued.

Your responsibility

The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to take this guidance fully into account, alongside the individual needs, preferences and values of their patients. The application of the recommendations in this guidance is at the discretion of health professionals and their individual patients and do not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.

Commissioners and/or providers have a responsibility to provide the funding required to enable the guidance to be applied when individual health professionals and their patients wish to use it, in accordance with the NHS Constitution. They should do so in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities.

  • National Institute for Health and Care Excellence (NICE) accreditation logo